Exenatide

Research overview

Key studies

1. DeFronzo et al., Diabetes Care (2005)

   Randomized, triple-blind, placebo-controlled, 30 weeks
   Model: Humans (adults with type 2 diabetes on metformin)

   HbA1c -0.78% (10 micrograms) and -0.40% (5 micrograms) versus +0.08% with placebo; body-weight change -2.8 and -1.6 kg; GI events most frequent ^4.

2. Holman et al., N Engl J Med (EXSCEL, NCT01144338) (2017)

   Randomized, double-blind, placebo-controlled cardiovascular outcomes trial, median 3.2 years
   Model: Humans (14,752 adults with type 2 diabetes)

   MACE 11.4% versus 12.2% (HR 0.91, 95% CI 0.83-1.00): noninferior, not superior; no significant differences in pancreatitis, pancreatic cancer or medullary thyroid carcinoma ^5.

3. Vijiaratnam et al., Lancet (Exenatide-PD3) (2025)

   Phase 3, multicentre, double-blind, randomized, placebo-controlled, 96 weeks
   Model: Humans (194 people with Parkinson's disease)

   MDS-UPDRS III off-medication scores worsened by 5.7 versus 4.5 points (p=0.47); no evidence of disease modification ^6.

4. Byetta prescribing information, Section 14.3 (add-on to insulin glargine) (2025)

   Randomized, double-blind, placebo-controlled, 30 weeks
   Model: Humans (259 adults with type 2 diabetes on titrated insulin glargine)

   HbA1c -1.7% versus -1.0% with placebo (difference -0.7%) ^1.

5. Eng et al., J Biol Chem (1992)

   Peptide isolation and characterization
   Model: Lizard venom and dispersed pancreatic acini

   Exendin-4 was isolated from Heloderma suspectum venom and characterized as an exendin-3 analogue ^7.

Dosing as stated on the FDA label

Quoted from the prescribing information for reference. Prescribing decisions belong to a licensed clinician; this is not a recommendation or instruction for use.

• Initiate at 5 micrograms subcutaneously twice daily at any time within the 60-minute period before the morning and evening meals (or before the two main meals of the day, about 6 hours or more apart); do not administer after a meal ^1.
• Based on clinical response, the dose can be increased to 10 micrograms twice daily after 1 month of therapy, to reduce the risk of GI adverse reactions ^1.
• Coadministration with other exenatide-containing products is not recommended. Administration instructions are set out in the label and are not reproduced here ^1.

Published adverse-event data

Reported in the cited trials or product labels. Frequencies apply to the stated population and do not transfer to other settings.

• Nausea
  44% versus 18% placebo
  Three 30-week add-on trials to metformin and/or sulfonylurea (n=963 vs 483) ¹ · Dose-dependent; frequency and severity decreased over time in most patients
• Vomiting
  13% versus 4%
  Same trials ¹ · Leading cause of withdrawal (1%) after nausea (3%)
• Diarrhea
  13% versus 6%
  Same trials ¹ · Not graded in table
• Feeling jittery
  9% versus 4%
  Same trials ¹ · Not graded in table
• Dizziness
  9% versus 6%
  Same trials ¹ · Not graded in table
• Headache
  9% versus 6%
  Same trials ¹ · Not graded in table
• Dyspepsia
  6% versus 3%
  Same trials ¹ · Not graded in table
• Hypoglycemia with a sulfonylurea
  14.4% (5 micrograms) and 35.7% (10 micrograms) versus 3.3% placebo; no severe events
  30-week add-on to sulfonylurea trial ¹ · Risk rises with insulin secretagogues

What is not known: Safety and effectiveness in pediatric patients have not been established, and effectiveness was not demonstrated in a pediatric trial ^1. No pharmacokinetic study has been performed in hepatic impairment ^1. Human relevance of thyroid C-cell adenomas in female rats is not stated as established in the label ^1. Current U.S. market availability is not consistent across FDA data sources reviewed ^2,3.

Regulatory status

Status

FDA-approved (initial U.S. approval 2005). As of 2026-10-24, Drugs@FDA lists Byetta (NDA 021773), Bydureon (NDA 022200) and Bydureon BCise (NDA 209210) as discontinued, while a generic exenatide injection label (Amneal) was updated on DailyMed in 2026; the openFDA record lists that ANDA's marketing status as discontinued, so current U.S. availability should be confirmed ^1,2,3.

United States (FDA)

FDA-approved (initial U.S. approval 2005). Drugs@FDA (openFDA, data updated 2026-10-23) lists Byetta, Bydureon and Bydureon BCise as discontinued; a generic exenatide injection label (Amneal, ANDA 206697) was updated on DailyMed in 2026 ^1,2,3.

Sport (WADA)

GLP-1 receptor agonists were not mentioned on the WADA 2026 Prohibited List page reviewed ^8.

Status varies by country and changes over time. How we describe regulatory status.

References

1. BYETTA (exenatide) injection, for subcutaneous use, prescribing information (DailyMed, effective 09/2025) FDA label (DailyMed). 2025
2. Exenatide injection (Amneal), prescribing information (DailyMed, effective 05/2026) FDA label (DailyMed). 2026
3. Drugs@FDA (openFDA) application records for exenatide (NDA 021773, NDA 022200, NDA 209210, ANDA 206697) U.S. FDA. 2026
4. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes Diabetes Care. 2005
5. Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes (EXSCEL) N Engl J Med. 2017
6. Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial Lancet. 2025
7. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom J Biol Chem. 1992
8. World Anti-Doping Agency Prohibited List 2026 (online version) WADA. 2026
9. PubChem compound record for exenatide PubChem. 2026